4.5 Article

Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: Scarification vaccination

期刊

VACCINE
卷 26, 期 23, 页码 2860-2872

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.03.044

关键词

vaccinia; smallpox vaccine; E3L

资金

  1. NIAID NIH HHS [AI 66501, AI66326, AI52347, R01 AI052347-02, U01 AI066326-03, U01 AI066326-01, U01 AI066326-02S1, U01 AI057303-05, R01 AI052347-04, R01 AI066501, U01 AI066326, R01 AI052347, U01 AI057303, R01 AI052347-01A1, U01 AI057303-02, U01 AI057303-03, U01 AI057303-01, R01 AI052347-03, U01 AI057303-04, R01 AI052347-05, U01 AI066326-02] Funding Source: Medline

向作者/读者索取更多资源

In this study, we evaluated the efficacy of vaccinia virus (VACV) containing mutations in the E3L virulence gene to protect mice against a lethal poxvirus challenge after vaccination by scarification. VACV strains with mutations in the E3L gene had significantly decreased pathogenicity, even in immune deficient mice, yet retained the ability to produce a potent Th1-dominated immune response in mice after vaccination by scarification, while protecting against challenge with wild type, pathogenic VACV. Initial experiments were done using the mouse-adapted, neurovirulent Western Reserve (WR) strain of vaccinia virus. Testing of the full E3L deletion mutation in the Copenhagen and NYCBH strains of VACV, which are more appropriate for use in humans, produced similar results. These results suggest that highly attenuated strains of VACV containing mutations in E3L have the potential for use as scarification administered vaccines. (c) 2008 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据